Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 6/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.32 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2022859 | 1.00 | GCK (0.45) | GCKAKR1C3PTGS2EPHX2IDO1 | |
| SCHEMBL2022570 | 0.89 | CCR6 (0.38) | GCK | |
| SCHEMBL2022568 | 0.89 | CCR6 (0.38) | GCK | |
| SCHEMBL2019074 | 0.87 | GCK (0.47) | GCKAKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL2019078 | 0.87 | GCK (0.47) | GCKAKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL2019838 | 0.87 | GCK (0.46) | GCKAKR1C3SMN1; SMN2AKR1C2AKR1C1 | |
| SCHEMBL2019842 | 0.87 | GCK (0.46) | GCKAKR1C3SMN1; SMN2AKR1C2AKR1C1 | |
| SCHEMBL2020445 | 0.85 | GCK (0.45) | GCKAKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL2020443 | 0.85 | GCK (0.45) | GCKAKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL2020259 | 0.85 | GCK (0.45) | GCKAKR1C3PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452977-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | GCK 188/4885AKR1C3 47/4885PTGS2 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.